Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313405775> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4313405775 endingPage "122.18" @default.
- W4313405775 startingPage "122.18" @default.
- W4313405775 abstract "Abstract Antagonizing antibodies against immune checkpoint inhibitory molecules (ICI) has gained an excellent reputation in immuno-oncology. Anti CTLA-4 and anti-PD-1 are among the first cancer checkpoint immunotherapies that got FDA approval to treat certain malignancies. However, not everyone can benefit from them due to the insufficient expression of the checkpoint marker on the surface of the tumor cells. CD94/NKG2A receptor is another inhibitory marker known to be expressed by natural killer cells and sub-population of CD8+ T cells. Specific peptides loaded by Qa-1b (mouse) or HLAE (human) on the surface of tumor cells, immune infiltrating lymphocytes, and myeloid cells are NKG2A ligand and are known to have a significant role in modulating anti-tumor effector cell responses. Our group previously developed a single-domain T-cell receptor-like antibody (EXX-1) with specificity for the Qa-1b/Qdm peptide complex, the ligand for the murine NKG2A/CD94 receptor. We have shown that treating tumor-bearing mice with EXX-1 as a single agent blocking antibody can create a modest delay in mice tumor growth and overall survival time. The presented study focused on utilizing EXX-1efficacy as a checkpoint blocking antibody in combination with a cancer vaccine. Our findings indicate that cancer vaccine effectiveness can be markedly enhanced when combined with EXX-1 antibody, leading to tumor-free survival in 35% of the mice compared to control groups. Taken together, our results indicate targeting the NKG2A axis through blocking Qa-1b/Qdm peptide complex is an effective means to treat cancer. Also, using HLAE/Qa-1b blocking antibody can improve the efficacy of the cancer vaccines and lead to better clinical outcomes when combined." @default.
- W4313405775 created "2023-01-06" @default.
- W4313405775 creator A5002322187 @default.
- W4313405775 date "2022-05-01" @default.
- W4313405775 modified "2023-09-23" @default.
- W4313405775 title "Cancer vaccines used in combination with TCR-like antibody blockade of the Qa-1b/Qdm complex, the ligand for the immune checkpoint NKG2A, induce anti-tumor immunity" @default.
- W4313405775 doi "https://doi.org/10.4049/jimmunol.208.supp.122.18" @default.
- W4313405775 hasPublicationYear "2022" @default.
- W4313405775 type Work @default.
- W4313405775 citedByCount "0" @default.
- W4313405775 crossrefType "journal-article" @default.
- W4313405775 hasAuthorship W4313405775A5002322187 @default.
- W4313405775 hasConcept C121608353 @default.
- W4313405775 hasConcept C126322002 @default.
- W4313405775 hasConcept C159654299 @default.
- W4313405775 hasConcept C167672396 @default.
- W4313405775 hasConcept C170493617 @default.
- W4313405775 hasConcept C203014093 @default.
- W4313405775 hasConcept C2777701055 @default.
- W4313405775 hasConcept C2778468042 @default.
- W4313405775 hasConcept C2780674031 @default.
- W4313405775 hasConcept C2780851360 @default.
- W4313405775 hasConcept C2908647359 @default.
- W4313405775 hasConcept C45121317 @default.
- W4313405775 hasConcept C502942594 @default.
- W4313405775 hasConcept C71924100 @default.
- W4313405775 hasConcept C86803240 @default.
- W4313405775 hasConcept C8891405 @default.
- W4313405775 hasConcept C99454951 @default.
- W4313405775 hasConceptScore W4313405775C121608353 @default.
- W4313405775 hasConceptScore W4313405775C126322002 @default.
- W4313405775 hasConceptScore W4313405775C159654299 @default.
- W4313405775 hasConceptScore W4313405775C167672396 @default.
- W4313405775 hasConceptScore W4313405775C170493617 @default.
- W4313405775 hasConceptScore W4313405775C203014093 @default.
- W4313405775 hasConceptScore W4313405775C2777701055 @default.
- W4313405775 hasConceptScore W4313405775C2778468042 @default.
- W4313405775 hasConceptScore W4313405775C2780674031 @default.
- W4313405775 hasConceptScore W4313405775C2780851360 @default.
- W4313405775 hasConceptScore W4313405775C2908647359 @default.
- W4313405775 hasConceptScore W4313405775C45121317 @default.
- W4313405775 hasConceptScore W4313405775C502942594 @default.
- W4313405775 hasConceptScore W4313405775C71924100 @default.
- W4313405775 hasConceptScore W4313405775C86803240 @default.
- W4313405775 hasConceptScore W4313405775C8891405 @default.
- W4313405775 hasConceptScore W4313405775C99454951 @default.
- W4313405775 hasIssue "1_Supplement" @default.
- W4313405775 hasLocation W43134057751 @default.
- W4313405775 hasOpenAccess W4313405775 @default.
- W4313405775 hasPrimaryLocation W43134057751 @default.
- W4313405775 hasRelatedWork W2171095535 @default.
- W4313405775 hasRelatedWork W2497869747 @default.
- W4313405775 hasRelatedWork W2612738915 @default.
- W4313405775 hasRelatedWork W2797580541 @default.
- W4313405775 hasRelatedWork W2820886885 @default.
- W4313405775 hasRelatedWork W2967658120 @default.
- W4313405775 hasRelatedWork W3199051113 @default.
- W4313405775 hasRelatedWork W3200165923 @default.
- W4313405775 hasRelatedWork W3204147903 @default.
- W4313405775 hasRelatedWork W4360983034 @default.
- W4313405775 hasVolume "208" @default.
- W4313405775 isParatext "false" @default.
- W4313405775 isRetracted "false" @default.
- W4313405775 workType "article" @default.